98 related articles for article (PubMed ID: 9857343)
1. "Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles".
Snyder PS
J Vet Intern Med; 1998; 12(6):478. PubMed ID: 9857343
[No Abstract] [Full Text] [Related]
2. Development of a new benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for treatment of heart failure in dogs.
Qian M; Chen T; Zhou D; Zhang Z; Zhang Q; Tang S; Xiao X
J Vet Pharmacol Ther; 2016 Feb; 39(1):98-101. PubMed ID: 26228576
[TBL] [Abstract][Full Text] [Related]
3. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: A retrospective study of 141 cases.
Kittleson M; Rishniw M; Pion P; Kass P
J Vet Intern Med; 2009; 23(5):953-4; author reply 955-6. PubMed ID: 19737176
[No Abstract] [Full Text] [Related]
4. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
Boswood A; McEwan JD; French A; Little C; Swift S; Smith S; Patteson M
Vet Rec; 2003 Oct; 153(14):439-40. PubMed ID: 14582738
[No Abstract] [Full Text] [Related]
5. MDL 100240.
Drugs R D; 1999 Apr; 1(4):348-9. PubMed ID: 10566061
[No Abstract] [Full Text] [Related]
6. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.
Hamlin RL; Nakayama T
J Vet Intern Med; 1998; 12(2):93-5. PubMed ID: 9560765
[TBL] [Abstract][Full Text] [Related]
7. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
Lefebvre HP; Laroute V; Concordet D; Toutain PL
J Vet Intern Med; 1999; 13(1):21-7. PubMed ID: 10052059
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
10. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.
De Lepeleire I; Van Hecken A; Verbesselt R; Kaiser G; Barner A; Holmes I; De Schepper PJ
Eur J Clin Pharmacol; 1988; 34(5):465-8. PubMed ID: 3203706
[TBL] [Abstract][Full Text] [Related]
11. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.
Pouchelon JL; Jamet N; Gouni V; Tissier R; Serres F; Carlos Sampedrano C; Castaignet M; Lefebvre HP; Chetboul V
J Vet Intern Med; 2008; 22(4):905-14. PubMed ID: 18482278
[TBL] [Abstract][Full Text] [Related]
12. Utility of urinary aldosterone measurement in quantitating RAAS activation.
Atkins CE; Lantis AC; Ames MK; Gardner SY
J Vet Pharmacol Ther; 2012 Oct; 35(5):512-5; author reply 516-8. PubMed ID: 22966900
[No Abstract] [Full Text] [Related]
13. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
Toutain PL; Lefebvre HP; Laroute V
J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers.
O'Grady MR; O'Sullivan ML; Minors SL; Horne R
J Vet Intern Med; 2009; 23(5):977-83. PubMed ID: 19572914
[TBL] [Abstract][Full Text] [Related]
15. [ACE inhibitors in dogs with subclinical chronic mitral insufficiency].
Kvart C; Häggström J; Pedersen HD
Tijdschr Diergeneeskd; 2003 Feb; 128(3):76-7. PubMed ID: 12616901
[No Abstract] [Full Text] [Related]
16. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs.
Tenhündfeld J; Wefstaedt P; Nolte IJ
J Am Vet Med Assoc; 2009 Apr; 234(8):1031-7. PubMed ID: 19366333
[TBL] [Abstract][Full Text] [Related]
18. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
Toutain PL; Lefebvre HP; King JN
J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
[TBL] [Abstract][Full Text] [Related]
19. Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617.
Kochak GM; Smith RA; Choi RL; John V; Tipnis V; Honc F; deSilva JK; Weidler DJ
Pharm Res; 1989 Apr; 6(4):328-31. PubMed ID: 2748520
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive and organ-protective effects of benazepril.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1653-71. PubMed ID: 21108548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
